Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
MannKind
MNKD
MannKind
Slow Formulary Coverage Will Hamper Diabetes Reach Yet Enable Rebound
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
10 May 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$7.00
41.3% undervalued
intrinsic discount
20 Aug
US$4.11
Loading
1Y
-23.5%
7D
10.2%
Author's Valuation
US$7.0
41.3% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$7.0
41.3% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-216m
388m
2014
2017
2020
2023
2025
2026
2028
Revenue US$388.3m
Earnings US$44.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
13.83%
Biotech revenue growth rate
11.73%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.82%
Calculation
US$44.39m
Earnings '28
x
72.12x
PE Ratio '28
=
US$3.20b
Market Cap '28
US$3.20b
Market Cap '28
/
375.88m
No. shares '28
=
US$8.52
Share Price '28
US$8.52
Share Price '28
Discounted to 2025 @ 6.84% p.a.
=
US$6.98
Fair Value '25
